COMPANY PROFILE / iPS CELLS & REGENERATIVE MEDICINE
Aspen Neuroscience
A privately held US biotech that grafts iPS cell-derived neurons, made from each patient's own skin, into the brain
Aspen Neuroscience is a privately held company based in San Diego, California. For Parkinson's disease it is developing an "autologous" therapy (sasineprocel, development code ANPD001) in which iPS cells made from the patient's own skin are turned into precursors of dopamine-producing neurons and transplanted into the putamen of the brain. Unlike an "allogeneic" therapy that uses another person's cells, it is designed so that no immunosuppressant is needed to prevent rejection. The cost is that cells must be made for each patient. In its Phase 1/2a trial (ASPIRO), transplants in 15 patients had been completed by 30 June 2026, and on 30 July 2026 the company announced that it had received RMAT designation from the US FDA. However, no product is approved, and the published results are company announcements (including conference presentations) from a small, open-label, uncontrolled group of patients. This profile sets out what the company has invested, who it works with, what has been confirmed and what remains open, using primary sources only.
- Aspen Neuroscience in 30 seconds, and where it stands in iPS cells and regenerative medicine
- The logo and how the name is written
- Where the company sits in iPS cells and regenerative medicine
- Scale of the company
- Resources committed to iPS cells and regenerative medicine
- Track record so far
- Plans ahead
- What the company is aiming for in iPS cells and regenerative medicine
- Partnership map
- Technologies, products and services
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Aspen Neuroscience in 30 seconds, and where it stands in iPS cells and regenerative medicine
California, U.S.The GMP manufacturing facility is also in the city
dopaminergic neural progenitorsTransplanted into the putamen under image guidance
(ANPD001)Adopted as an international nonproprietary name in March 2026
In terms of the three types of company in this field, Aspen Neuroscience is an iPS cell & cell therapy company, and its treatment is iPS cell-derived neural cells made from each patient's own cells, one patient at a time (autologous) Sourced. It is often set against the allogeneic iPS cell-derived neural cell product that received conditional and time-limited approval in Japan in March 2026 (Sumitomo Pharma's Amchepry), but the two are designed differently and this is not a comparison of which is better. An allogeneic product can be made in advance but needs immunosuppressants; an autologous one needs none but has to be made for each patient. Aspen's published data are from a small, open-label, uncontrolled group of patients, compared with each patient's own state before transplant. As a private company it has no statutory disclosure such as an annual report, and most of the information comes from the company's own announcements. This article does not judge the merits of any product or whether a treatment is appropriate; it sets out the company's current state from primary sources.
2. The logo and how the name is written
A note on names: the company is Aspen Neuroscience, Inc.; take care not to confuse it with other companies of the same name. The development code of the lead product is ANPD001 (autologous dopaminergic neural progenitor cells, DANPC). In March 2026 the WHO published sasineprocel as its international nonproprietary name (INN); the company says the review by the USAN Council of the American Medical Association has also been passed and publication is awaited. The clinical trial is called ASPIRO (Autologous-derived Study of a Parkinson's Investigational Regenerative therapy in an Open-label trial).
Official site: https://aspenneuroscience.com/3. Where the company sits in iPS cells and regenerative medicine
In terms of how it treats patients, Aspen is of the type that makes iPS cell-derived nerve cells from the patient's own cells (autologous). Cells taken in a small skin biopsy are made into iPS cells and differentiated into the cells one step before dopamine-producing neurons (DANPC), and the frozen preparation is transplanted into the putamen of the brain under image guidance Sourced. For the difference between allogeneic and autologous cells, see our explainer on autologous and allogeneic cells in this series; for how neurons relate to Parkinson's disease, see our explainer on iPS-derived neurons and Parkinson's disease.
4. Scale of the company
Aspen is privately held, and financial information such as revenue, profit or loss and headcount is not published. What is published is its fundraising history Sourced (amounts in US dollars).
| When | Round | Amount | Main investors (company's account) |
|---|---|---|---|
| 2018 | Seed | US$6.5 million | Led by Domain Associates and Axon Ventures. Alexandria Venture Investments, ARCH Venture Partners, OrbiMed and Section 32 also took part |
| Early 2020 | Series A | US$70 million | Led by OrbiMed. ARCH, Frazier Healthcare Partners, Domain Associates, Section 32 and Sam Altman also took part |
| Early 2022 | Series B | US$147 million | Co-led by Google Ventures, LYFE Capital and Revelation Partners |
| 20 November 2025 | Series C | US$115 million | Co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences and Revelation Partners. New investors include Kite (a Gilead company) |
The company says it has raised more than US$340 million in total, including an US$8 million grant from the California Institute for Regenerative Medicine (CIRM). R&D expense, headcount, cash balance and profit or loss are not published.
Because it is a private company, there is no audited document of the kind of an annual securities report or an SEC filing. The amounts above are the company's own announcements, and this article does not use valuations estimated by research firms for venture investors, or press speculation about a public listing. Clinical results too rest mainly on conference presentations and the company's announcements, and we have not been able to confirm any third-party evaluation Not yet confirmed.
5. Resources committed to iPS cells and regenerative medicine
Aspen is a company focused on autologous iPS cell therapy for Parkinson's disease, so the company's overall resources are what it commits to this field. As a private company it does not publish a breakdown of staff or spending. We separate what could be confirmed from what could not.
| Type of resource | Details | Category |
|---|---|---|
| People (management) | The official site lists 13 members of the management team. President and CEO is Damien McDevitt (formerly CEO of Akcea Therapeutics), CSO is Xiaokui Zhang, CMO is Revati Shreeniwas (appointed January 2025), CCO is Lisa Johnson-Pratt, CFO is Dalen Meeter and CTO is Kim Raineri. Jeanne Loring is a co-founder. The total number of employees is not disclosed | Sourced |
| Money (fundraising) | More than US$340 million in total (including an US$8 million CIRM grant). The latest is the US$115 million Series C of November 2025. The stated uses are continuing clinical trials, scaling manufacturing in readiness for clinical and commercial demand, and additional neurological pipeline programmes | Sourced |
| Money (amounts of R&D and capital expenditure) | The amounts of R&D expense and investment in manufacturing facilities are not disclosed | Could not be confirmed |
| Manufacturing facilities | A GMP facility (about 22,000 square feet) in San Diego, with room for about 8,000 square feet of future automation (announcement of January 2025). In January 2026 it announced that a manufacturing facility for late-stage clinical trials and commercialisation had entered qualification | Sourced |
| Investment in and acquisition of other companies | No acquisition of or investment in other companies is stated in the official announcements | Could not be confirmed |
| Technology brought in (licences and collaborations) | A collaboration and licence agreement with Cell X Technologies on automating iPS cell processes (October 2024; payment not disclosed). A collaboration with Mytos on automating DANPC manufacturing (January 2025) | Sourced |
| Universities and public funding | A grant of about US$8 million from the California Institute for Regenerative Medicine (CIRM), which funded cohorts 1 and 2 of the ASPIRO trial (grant number CLIN2-15547). The trial is run at nine US sites (UCSF, UCLA, UCSD, UC Irvine, Scripps Health, Banner Health, the University of Colorado, Emory University and the Feinstein Institutes) | Sourced |
6. Track record so far
| When | What happened | What it means |
|---|---|---|
| 2018 | Founded. Seed funding of US$6.5 million | Founded to treat Parkinson's disease with autologous iPS cells |
| 2020 and 2022 | Series A (US$70 million) and Series B (US$147 million) | Development funds towards the IND (the application to begin trials) |
| January 2024 | The ASPIRO trial (Phase 1/2a) began (the start date on ClinicalTrials.gov is 23 January 2024) | The company describes it as the first multicentre trial of an autologous cell therapy of its kind |
| October 2024 | Collaboration and licence agreement with Cell X Technologies | Automating iPS cell processes |
| January 2025 | Announced the expansion of the GMP facility and the collaboration with Mytos. Announced completion of cohorts 1 and 2 | Scaling up manufacturing |
| May 2025 | Announced six-month results for the first three patients (IAPRD 2025). The company says a paper was also published in Parkinsonism & Related Disorders | Early results |
| 20 November 2025 | Announced the US$115 million Series C. An executive of Kite (a Gilead company) joined the board | Funds for late-stage development and preparing for commercialisation |
| 8 January 2026 | Dosing of cohort 3 completed. First use of the commercial preparation (delivered frozen, thawed and injected on site: "thaw-and-inject") | Change of preparation |
| March 2026 | The WHO published the international nonproprietary name sasineprocel (12th). Presented 12-month results for the first eight patients at AD/PD 2026 (18th) | Name fixed; interim results |
| 30 June 2026 | Dosing of cohorts 3 and 4 completed. 15 patients dosed in all | The last step before a later-stage trial |
| 30 July 2026 | Announced that it had received RMAT designation from the US FDA | Closer discussions with the FDA and a possibility of priority review |
| 18 September 2026 | Announced that preclinical data had been published in the journal Cell Stem Cell | Evidence on manufacturing quality control and preclinical work |
Clinical results (the company's announcements, within what the primary sources say)
What follows are results Aspen has published. The trial is open-label and uncontrolled, and the comparison is with each patient's own state before transplant. All come from the company's announcements (including conference presentations). We have not been able to confirm an evaluation by regulators. The company says the six-month results for the first three patients were published in a peer-reviewed journal, but we have not checked the text of the paper. The results do not guarantee any treatment effect or safety, and are not medical advice.
| Time point and patients | Details (company's announcement) | Category |
|---|---|---|
| 6 months (first three patients, 5 million cells per side into the putamen) | The physician-rated motor score (MDS-UPDRS Part III, off state) improved by 45% on average, and the patient-reported daily-living score (Part II) by 71% on average. Adjusted off time fell by 2.0 hours on average and "good on" time rose by 1.5 hours on average. No bleeding or serious surgical complications, and no reports of dyskinesia related to the trial treatment | Sourced |
| 12 months (first eight patients: four low dose, four high dose) | Good-on time rose by 2.1 hours on average at the low dose and 2.4 hours at the high dose. MDS-UPDRS Part III (off) changed by −15.5 points (low dose) and −13.5 points (high dose); the lower the score, the milder the symptoms. Part II changed by −5.3 and −2.3 points. Average improvement in PDQ-39 (quality of life) was 51.6% and 28.5%. In several patients the levodopa-equivalent dose fell. Imaging (FDOPA PET) suggested that the cells survived and engrafted | Sourced |
| Safety (at 12 months) | No serious surgery-related adverse events, no serious dyskinesia, and no symptomatic bleeding or infarction. No immunosuppressants are used | Sourced |
| Trial design | Open-label, multicentre and dose-escalating. Patients aged 50 to 70 with moderate to advanced Parkinson's disease who respond to levodopa. The primary objective is the safety and tolerability of dosing into the putamen on both sides, and the secondary objective is change in clinical outcomes. The low dose is 5 million cells per side and the high dose 5 to 10 million cells per side. Follow-up is five years, with long-term safety follow-up to year 15 | Sourced |
7. Plans ahead
long-term safety to year 15Primary completion on ClinicalTrials.gov is estimated at March 2027
| Planned or in-development item | Where it stands (company's account) | Category |
|---|---|---|
| Phase 3 trial of sasineprocel (ANPD001) | In March 2026 the Chief Medical Officer said the company would move into a Phase 3 trial within 2026; the June announcement said it was preparing to start Phase 3, and the September announcement said it was entering Phase 3. We could not find a registration record for a Phase 3 trial (ClinicalTrials.gov) at the time of writing. Patient numbers, design and primary endpoint are not disclosed | Not yet confirmed |
| ASPIRO trial (Phase 1/2a) | 15 patients have been dosed across cohorts 1 to 4. Cohorts 3 and 4 used the commercial preparation (delivered frozen, thawed and injected on site). Cohorts 1 and 2 were funded by the CIRM grant. ClinicalTrials.gov still shows an estimated enrolment of 9, which differs from the company's announcements (15), so it may be behind on updates | Sourced |
| Scaling and automating manufacturing | Scaling up manufacturing and optimising the process in line with the requirements of later-stage trials. Plans to automate the iPS cell process with Cell X Technologies' automation platform and the differentiation into DANPC with Mytos's automation | Not yet confirmed |
| Other autologous iPS cell products | The company says it is researching several candidates for cell replacement therapy in the central nervous system, including sporadic and genetic Parkinson's disease. Individual product names and stages are not disclosed | Not yet confirmed |
None of the following appears in the primary sources, or the company has not disclosed it Not yet confirmed.
The start date, patient numbers and design of the Phase 3 trial / when a US approval application will be filed / the time and cost needed to manufacture for one patient / commercial production capacity / headcount, cash balance and profit or loss / development plans outside the United States (including Japan) / plans for a public listing (there is speculation in the press, but the company has not said so). RMAT designation brings benefits such as closer discussions with the FDA and a possibility of priority review, but it does not guarantee the prospect of approval.
8. What the company is aiming for in iPS cells and regenerative medicine
This section includes things the company does not say directly. We set them out as inferences within what the primary sources support, with the evidence for each.
| What the evidence suggests | Primary information it rests on | Category |
|---|---|---|
| It is aiming first for the first approval in the United States of an autologous iPS cell-derived neural cell therapy | The company repeatedly describes sasineprocel as the most advanced autologous cell therapy in the United States. It has obtained Fast Track and RMAT designations, talks of Phase 3 and of preparing for commercialisation, and has appointed a chief commercial officer | Inference |
| The decisive point is making manufacturing per patient stable at commercial scale | It has entered into automation collaborations for both the iPS cell process and the differentiation into DANPC, and has set aside room for automation in the GMP facility. It has switched to a frozen-delivery, thaw-and-inject preparation | Inference |
| The centre of its differentiation is not needing immunosuppressants | As benefits of being autologous, the company states that adverse events associated with immunosuppressants and the management of taking them are avoided, and that patients with contraindications can be treated | Sourced |
| It plans to extend from Parkinson's disease to other neurological diseases | It writes of starting with neurodegenerative diseases and of advancing additional neurological pipeline programmes. These are also among the uses of the Series C funds | Inference |
| Business in Japan could not be confirmed within the primary sources | There is no mention of consultation with Japanese regulators, Japanese trials or alliances with Japanese companies | Sourced |
The reading that "the decisive point is per-patient manufacturing" rests on the fact that the company's use of funds and the content of its collaborations lean towards manufacturing rather than research. The stated uses of the US$115 million Series C include, in addition to continuing the trial, scaling manufacturing in readiness for clinical and future commercial demand Sourced. The two collaborations signed since October 2024 are both about automation. Unlike an allogeneic therapy, an autologous therapy cannot be made ahead of time: each patient's journey from biopsy to transplant has to be run as a process. We think that whether the company can show it can run that process stably at commercial scale will be the key from Phase 3 onwards Not yet confirmed. The time and cost for one patient have not been published. This inference does not say which is better, allogeneic or autologous.
9. Partnership map
How to read the figure: Aspen has no joint development or out-licensing agreement with a pharmaceutical company; its funds come from investors and CIRM, and it advances manufacturing automation through collaborations with equipment and technology companies. The most visible involvement of a large pharma company is that Kite (a Gilead company) took part in the Series C as a new investor and one of its executives joined the board Sourced. That is an investment and a board seat, not a joint development or sales agreement.
10. Technologies, products and services
| Item | Details (from official announcements) |
|---|---|
| sasineprocel (ANPD001) | A single-dose autologous cell therapy in which iPS cells made from a small skin biopsy of the patient are differentiated into the cells one step before dopamine-producing neurons (DANPC). Delivered to both sides of the putamen, behind the posterior commissure, under MRI guidance. The company describes it as a specific combination of cells (a composition of several cell types) |
| Manufacturing (genetic quality control) | At each step, cell quality is checked with the company's own machine-learning-based genomic tests (PluriTest, NeuriTest, GraftTest, DopaTest and others). In September 2026 it announced that a paper setting out a quality-control framework using whole-genome and RNA analysis had been published in Cell Stem Cell |
| Preparation | For cohorts 3 and 4, a commercial preparation that is cryopreserved, delivered to the clinical site, and thawed and injected on arrival. The company says it was judged equivalent to the preparation used in cohorts 1 and 2 in preclinical work |
| Delivery system | A proprietary delivery device combining a metered syringe with MRI guidance. The company says it has sub-millimetre accuracy and aims at minimally invasive surgery |
| Manufacturing facility | A GMP facility in San Diego (about 22,000 square feet). In January 2026 it entered the qualification stage as a facility for late-stage trials and commercialisation |
In this company's product, what matters for materials and processes is the step that brings cells that vary from patient to patient to preparations of the same quality Sourced. An allogeneic product can be made from a cell bank whose quality has been checked in advance. An autologous one starts each time from a different person's skin cells, so the whole sequence of making iPS cells, checking quality, differentiating, freezing and shipping is run for one patient at a time. The company's use of whole-genome and RNA tests with machine learning at each step, and its separate collaborations with two companies to automate the iPS cell step and the differentiation step, can be read as ways of reducing this variability and the burden of manual work Not yet confirmed.
The company also explains that a preparation delivered frozen and thawed and injected on site reduces the burden of cell preparation at hospitals. The cryopreservation solution, survival after thawing and the step of filling cells into the transplant syringe matter here, but the specifications of the materials and equipment have not been disclosed. See also our explainers in this series on autologous and allogeneic cells, cell manufacturing and cell banks, and GMP.
11. The risks this company carries
| Risk | Details | Category |
|---|---|---|
| Small results and little third-party evaluation | The published results are from small, open-label, uncontrolled, dose-escalating groups (three patients at six months and eight at twelve months), comparing each patient with the state before transplant. They rest mainly on company announcements and conference presentations, and no regulatory evaluation can be confirmed | Sourced |
| Change of preparation | For cohorts 3 and 4 it switched from a fresh preparation to a commercial one delivered frozen. The company says they are equivalent in preclinical work, but clinical results for cohorts 3 and 4 had not been published at the time of writing | Sourced |
| The burden of brain surgery | Because dosing is intracranial, surgical complications are possible. The company has announced that no serious surgery-related adverse events or symptomatic bleeding have been observed so far. Patients with, for example, cognitive decline are excluded under the exclusion criteria | Sourced |
| The burden of per-patient manufacturing | Each patient is manufactured for from biopsy to shipment. Time, cost and failure rate are not disclosed. There is as yet no track record of stable supply at commercial scale | Inference |
| Long-term safety | Because the transplanted cells remain for a long time, tumour formation and overgrowth of the graft need to be checked over the long term. Follow-up is set at five years, with long-term safety follow-up to year 15 | Sourced |
| Little disclosure | Being private, there is no statutory disclosure of finances, headcount, manufacturing yield or a full list of adverse events. Apart from the fundraising history (more than US$340 million in total), its financial position is unknown | Sourced |
| Competing therapies | In Japan an allogeneic iPS cell-derived dopaminergic neural progenitor product received conditional and time-limited approval in March 2026, and other allogeneic stem cell-derived products are being developed. The company stresses the advantages of autologous cells, but a comparison with allogeneic products cannot be evaluated because no trial has been run under the same conditions | Sourced |
| Delay in development | We could not find a registration record for a Phase 3 trial, so the start date rests on the company's statements. The start may be delayed, or agreement with regulators on the design may not be reached | Inference |
12. Glossary
- Autologous
- Using the patient's own cells. Rejection is less likely and immunosuppressants are in principle not needed. Cells must be made for each patient.
- Allogeneic
- Using cells from another person (a donor) rather than from the patient. They can be made in advance, but drugs to suppress rejection are needed.
- DANPC
- Dopaminergic neural progenitor cells. Cells one step before becoming dopamine-producing neurons.
- Putamen
- A structure deep in the brain involved in controlling movement. In Parkinson's disease the supply of dopamine here falls.
- MDS-UPDRS
- An international scale for rating Parkinson's disease. Part II covers daily living (answered by the patient) and Part III covers motor symptoms (scored by the physician at examination). The lower the score, the milder the symptoms.
- Off state and good on
- The time when the effect of medication is weak (off), and the time when medication is working well with few side effects (good on).
- PDQ-39
- A 39-item questionnaire in which patients rate their own quality of life with Parkinson's disease.
- RMAT designation
- The US FDA's preferential designation for regenerative medicine therapies. It brings closer discussions with the FDA and the possibility of priority review and accelerated approval. It does not guarantee approval.
- Fast Track designation
- A US FDA designation to speed the development and review of drugs for serious conditions.
- CIRM
- The California Institute for Regenerative Medicine. A state agency that funds stem cell and gene therapy research.
- GMP
- Good manufacturing practice. The standard for manufacturing control and quality control of drugs and regenerative medicine products.
- FDOPA PET
- A scan that shows dopaminergic function in the brain. Used as a guide to cell engraftment and function.
13. References
- Aspen Neuroscience Press release, "Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson's Disease" (30 July 2026). https://aspenneuroscience.com/aspen-neuroscience-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-sasineprocel-anpd001-to-treat-parkinsons-disease/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson's Disease" (30 June 2026). https://aspenneuroscience.com/aspen-neuroscience-announces-completion-of-cohort-3-and-4-dosing-in-aspiro-phase-1-2a-trial-of-sasineprocel-for-parkinsons-disease/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces Positive 12-Month Data from its ASPIRO Clinical Trial in a Late-Breaking Oral Presentation at the AD/PD 2026 International Conference" (18 March 2026). https://aspenneuroscience.com/aspen-neuroscience-announces-positive-12-month-data-from-its-aspiro-clinical-trial-in-a-late-breaking-oral-presentation-at-t/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson's Disease" (7 May 2025). https://aspenneuroscience.com/aspen-neuroscience-announces-6-month-aspiro-phase-1-2a-clinical-trial-results-of-personalized-cell-therapy-for-parkinsons-disease/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in Cell Stem Cell" (18 September 2026). https://aspenneuroscience.com/aspen-neuroscience-announces-publication-of-sasineprocel-preclinical-data-in-cell-stem-cell/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs" (20 November 2025). https://aspenneuroscience.com/aspen-neuroscience-announces-115-million-series-c-financing-to-accelerate-personalized-cell-therapy-programs/
- Aspen Neuroscience Investor information (history of the seed round and Series A to C). https://aspenneuroscience.com/investor-relations/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces Collaboration and License Agreement with Cell X Technologies" (8 October 2024). https://aspenneuroscience.com/aspen-neuroscience-announces-collaboration-and-license-agreement-with-cell-x-technologies/
- Aspen Neuroscience Press release, "Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson's Disease" (8 January 2025). The GMP facility and the collaboration with Mytos. https://aspenneuroscience.com/aspen-neuroscience-advances-the-automated-production-of-personalized-autologous-cell-therapy-for-parkinsons-disease/
- Aspen Neuroscience Press release, "Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson's Disease" (13 January 2025). https://aspenneuroscience.com/aspen-neuroscience-announces-completion-of-first-and-second-cohorts-in-aspiro-phase-1-2a-trial-for-parkinsons-disease/
- Aspen Neuroscience Leadership Team. https://aspenneuroscience.com/leadership-team/
- Aspen Neuroscience Technology Overview. https://aspenneuroscience.com/technology-overview/
- U.S. National Library of Medicine ClinicalTrials.gov NCT06344026, "Phase 1/2a Study of ANPD001 in Parkinson Disease". https://clinicaltrials.gov/study/NCT06344026
- Sumitomo Pharma "Notice of receipt of marketing approval in Japan for Amchepry, allogeneic iPS cell-derived dopaminergic neural progenitor cells" (6 March 2026) (in Japanese). Used to confirm the competing allogeneic product. https://www.sumitomo-pharma.co.jp/news/20260306.html
- Aspen Neuroscience Official website (source of the logo). https://aspenneuroscience.com/
14. Claim-to-source audit
Last updated 1 October 2026 / Troy Technical
The figures in this article are based on Aspen Neuroscience's official press releases and investor information, and on ClinicalTrials.gov. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of the primary sources, not statements made by the company. This article does not recommend any treatment or product and is not medical advice.